EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy

M A Gouda, V Subbiah

ESMO Open · 2023-04 · 8 (2) · 100788

DOI: 10.1016/j.esmoop.2023.100788 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ESMO Open, 2023-04. Verfasst von M A Gouda und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA; Depa…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma. Die Arbeit wurde bisher 110-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NCATS NIH HHS, Center for Clinical and Translational Sciences, University of Texas Health Science Center at Houston.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BRAF activation occurs as part of the mitogen-activated protein kinase (MAPK) cellular signaling pathway which leads to increased cellular proliferation and survival. Mutations in BRAF can result in unbridled activation of downstream kinases with subsequent uncontrolled cellular growth that formulate the basis for oncogenesis in multiple tumor types. Targeting BRAF by selective inhibitors has been one of the early successes in precision oncology. Agents have been explored either as monotherapy or in combination with MEK inhibition in BRAF V600-mutant pan-cancers and with EGFR inhibition in colorectal cancer. Spectrum of BRAF inhibition has evolved from being melanoma-specific to being a pan-cancer target. In this article, we review BRAF and MEK inhibitor drug development journey from tissue-specific melanoma, non-small-cell lung cancer, and anaplastic thyroid cancer to tissue-agnostic approvals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsMelanomaHumansProto-Oncogene Proteins B-rafPrecision MedicineProtein Kinase InhibitorsMitogen-Activated Protein Kinase Kinases

Stichwörter der Autor:innen

BRAFMEKcancerprecision oncologytargeted therapy

Substanzen

Proto-Oncogene Proteins B-rafProtein Kinase InhibitorsMitogen-Activated Protein Kinase KinasesBRAF protein, human

Autor:innen und Institutionen

  • Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of Clinical Oncology, Faculty of Medicine, Menoufia University,…
  • Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA; Division of Pediatrics, The University of Texas MD Anderson Cancer Center,…

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS
  • Center for Clinical and Translational Sciences, University of Texas Health Science Center at Houston
  • National Institutes of Health
  • Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy
  • National Cancer Institute
  • Cancer Prevention and Research Institute of Texas
  • University of Texas MD Anderson Cancer Center

Zitieren

APA

Gouda, M. A., & Subbiah, V. (2023). Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy. ESMO Open, 8(2), 100788. https://doi.org/10.1016/j.esmoop.2023.100788

Vancouver

Gouda MA, Subbiah V. Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy. ESMO Open. 2023;8(2):100788. doi:10.1016/j.esmoop.2023.100788

BibTeX
@article{Gouda2023,
  author = {Gouda, M A and Subbiah, V},
  title = {Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy},
  journal = {ESMO Open},
  year = {2023},
  volume = {8},
  number = {2},
  pages = {100788},
  doi = {10.1016/j.esmoop.2023.100788}
}
Kostenlos starten →